Showing 1 - 20 results of 35 for search '"НЕЙРОТРОФИЧЕСКИЕ ФАКТОРЫ"', query time: 0.63s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Academic Journal

    Contributors: The study was supported by the Russian Science Foundation and the Republic of Crimea grant No. 22-15-20035, https://rscf.ru/project/22-15-20035., Исследование поддержано грантом Российского научного фонда и Республики Крым № 22-15-20035, https://rscf.ru/project/22-15-20035.

    Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 6 (2022); 12-19 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 6 (2022); 12-19 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-6

    File Description: application/pdf

    Relation: https://nnp.ima-press.net/nnp/article/view/1915/1471; Батышева ТТ, Крапивкин АИ, Царегородцев АД и др. Реабилитация детей с поражением центральной нервной системы. Российский вестник перинатологии и педиатрии. 2017;62(6):7-15. doi:10.21508/1027-4065-2017-62-6-7-15; Батышева ТТ, Трепилец ВМ, Климов ЮА и др. Современный взгляд на проблему детского церебрального паралича. Детская и подростковая реабилитация. 2016;2(27):5-9.; Бадалян ЛО, Журба ЛТ, Тимонина ОВ. Детские церебральные параличи. Москва; 2013. 325 с.; Корсунская ЛЛ, Савчук EO, Ларина НВ и др. Эффективность применения комбинированной методики «Неинвазивный интерфейс «Мозг – Компьютер – Экзоскелет кисти» в сочетании с ноотропной терапией в реабилитации детей с детским церебральным параличом. Медицинский вестник Северного Кавказа. 2020;15(1):58-61. doi:10.14300/mnnc.2020.15012; Lopresti AL, Maker GL, Hood SD, Drummond PD. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:102-11. doi:10.1016/j.pnpbp.2013.09.017. Epub 2013 Oct 5.; El-Tamawy MS, Abd-Allah F, Ahmed SM, et al. Aerobic exercises enhance cognitive functions and brain derived neurotrophic factor in ischemic stroke patients. NeuroRehabilitation. 2014;34(1):209-13. doi:10.3233/NRE-131020; Tanaka R, Miyasaka Y, Yada K, et al. Basic fibroblast growth factor increases regional cerebral blood flow and reducesinfarct size after experimental ischemia in a rat model. Stroke. 1995;26(11):2154-8. doi:10.1161/01.STR.26.11.2154; Крыжановская СЮ, Запара МА, Глазачев ОС. Нейротрофины и адаптация к средовым стимулам: возможности расширения «терапевтического потенциала» (краткий обзор). Вестник Международной Академии Наук (Русская секция). 2020;(1):36-43.; Гомазков ОА. Нейрогенез как адаптивная функция мозга. Москва: НИИ биомедицинской химии; 2014. 86 с.; Castren E, Hen R. Neuronal plasticity and antidepressant actions. Trends Neurosci. 2013 May;36(5):259-67. doi:10.1016/j.tins.2012.12.010. Epub 2013 Feb 1.; Cramer SC, Sur M, Dobkin BH, et al. Harnessing neuroplasticity for clinical applications. Brain. 2011 Jun;134(Pt 6):1591-609. doi:10.1093/brain/awr039. Epub 2011 Apr 10.; Ventimiglia R, Jones BE, Müller A. A quantitative method for morphometric analysis in neuronal cell culture: unbiased estimation of neuron area and number of branch points. J Neurosci Methods. 1995 Mar;57(1):63-6. doi:10.1016/0165-0270(94)00126-2; Alcantara CC, Garcia-Salazar LF, Silva-Couto MA, et al. Post-stroke BDNF Concentration Changes Following Physical Exercise: A Systematic Review. Front Neurol. 2018 Aug 28;9:637. doi:10.3389/fneur.2018.00637; Kowianski P, Lietzau G, Czuba E, et al. BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity. Cell Mol Neurobiol. 2018 Apr;38(3):579-93. doi:10.1007/s10571-017-0510-4. Epub 2017 Jun 16.; Lin TN, Te J, Lee M, et al. Induction of basic fibroblast growth factor (bFGF) expression following focal cerebral ischemia. Brain Res Mol Brain Res. 1997 Oct 3;49(1-2):255-65. doi:10.1016/s0169-328x(97)00152-6; Lucini C, D’Angelo L, Cacialli P, et al. BDNF, Brain, and Regeneration: Insights from Zebrafish. Int J Mol Sci. 2018 Oct 13;19(10):3155. doi:10.3390/ijms19103155; Jin-qiao S, Bin S, Wen-hao Z, Yi Y. Basic fibroblast growth factor stimulates the proliferation and differentiation of neural stem cells in neonatal rats after ischemic brain injury. Brain Dev. 2009 May;31(5):331-40. doi:10.1016/j.braindev.2008.06.005. Epub 2008 Jul 26.; Kiprianova I, Schindowski K, von Bohlen und Halbach O, et al. Enlarged infarct volume and loss of BDNF mRNA induction following brain ischemia in mice lacking FGF-2. Exp Neurol. 2004 Oct;189(2):252-60. doi:10.1016/j.expneurol.2004.06.004; Leker RR, Soldner F, Velasco I, et al. Long-lasting regeneration after ischemia in the cerebral cortex. Stroke. 2007 Jan;38(1):153-61. doi:10.1161/01.STR.0000252156.65953.a9. Epub 2006 Nov 22.; Naylor M, Bowen KK, Sailor KA, et al. Preconditioning-induced ischemic tolerance stimulates growth factor expression and neurogenesis in adult rat hippocampus. Neurochem Int. 2005 Dec;47(8):565-72. doi:10.1016/j.neuint.2005.07.003. Epub 2005 Sep 9.; Okada T, Kataoka Y, Takeshita A, et al. Effects of transient forebrain ischemia on the hippocampus of the Mongolian gerbil (Meriones unguiculatus): an immunohistochemical study. Zoolog Sci. 2013 Jun;30(6):484-9. doi:10.2108/zsj.30.484; Imamura T. Physiological functions and underlying mechanisms of fibroblast growth factor (FGF) family members: recent findings and implications for their pharmacological application. Biol Pharm Bull. 2014;37(7):1081-9. doi:10.1248/bpb.b14-00265; Lenhard T, Schober A, Suter-Crazzolara C, Unsicker K. Fibroblast growth factor-2 requires glial-cell-line-derived neurotrophic factor for exerting its neuroprotective actions on glutamate-lesioned hippocampal neurons. Mol Cell Neurosci. 2002 Jun;20(2):181-97. doi:10.1006/mcne.2002.1134; Zechel S, Werner S, Unsicker K, von Bohlen und Halbach O. Expression and functions of fibroblast growth factor 2 (FGF-2) in hippocampal formation. Neuroscientist. 2010 Aug;16(4):357-73. doi:10.1177/1073858410371513. Epub 2010 Jun 25.; Speliotes EK, Caday CG, Do T, et al. Increased expression of basic fibroblast growth factor (bFGF) following focal cerebral infarction in the rat. Brain Res Mol Brain Res. 1996 Jul;39(1-2):31-42. doi:10.1016/0169-328x(95)00351-r; Zhao XC, Zhang LM, Tong DY, et al. Propofol increases expression of basic fibroblast growth factor after transient cerebral ischemia in rats. Neurochem Res. 2013 Mar;38(3):530-7. doi:10.1007/s11064-012-0945-4. Epub 2012 Dec 18.; Watanabe T, Okuda Y, Nonoguchi N, et al. Postischemic intraventricular administration of FGF-2 expressing adenoviral vectors improves neurologic outcome and reduces infarct volume after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2004 Nov;24(11):1205-13. doi:10.1097/01.WCB.0000136525.75839.41; Wei OY, Huang YL, Da CD, Cheng JS. Alteration of basic fibroblast growth factor expression in rat during cerebral ischemia. Acta Pharmacol Sin. 2000 Apr;21(4):296-300.; Ye J, Lin H, Mu J, et al. Effect of basic fibroblast growth factor on hippocampal cholinergic neurons in a rodent model of ischaemic encephalopathy. Basic Clin Pharmacol Toxicol. 2010 Dec;107(6):931-9. doi:10.1111/j.1742-7843.2010.00603.x; Xiao N, Thor D, Yu WY. Neurotrophins BDNF and NT4/5 accelerate dental pulp stem cell migration. Biomed J. 2021 Jun;44(3):363-8. doi:10.1016/j.bj.2020.03.010. Epub 2020 Apr 21.; Altar CA, Boylan CB, Fritsche M, et al. Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions. J Neurochem. 1994 Sep;63(3):1021-32. doi:10.1046/j.1471-4159.1994.63031021.x; Aarse J, Herlitze S, Manahan-Vaughan D. The requirement of BDNF for hippocampal synaptic plasticity is experience-dependent. Hippocampus. 2016 Jun;26(6):739-51. doi:10.1002/hipo.22555. Epub 2016 Jan 19.; Benarroch EE. Brain-derived neurotrophic factor: Regulation, effects, and potential clinical relevance. Neurology. 2015 Apr 21;84(16):1693-704. doi:10.1212/WNL.0000000000001507. Epub 2015 Mar 27.; Brunelli A, Dimauro I, Sgro P, et al. Acute exercise modulates BDNF and pro-BDNF protein content in immune cells. Med Sci Sports Exerc. 2012 Oct;44(10):1871-80. doi:10.1249/MSS.0b013e31825ab69b; Widmer HR, Hefti F. Stimulation of GABAergic neuron differentiation by NT-4/5 in cultures of rat cerebral cortex. Brain Res Dev Brain Res. 1994 Jul 15;80(1-2):279-84. doi:10.1016/0165-3806(94)90114-7; Friedman HS, Tucker JS, Schwartz JE, et al. Childhood conscientiousness and longevity: health behaviors and cause of death. J Pers Soc Psychol. 1995 Apr;68(4):696-703. doi:10.1037//0022-3514.68.4.696

  6. 6
  7. 7
  8. 8
    Academic Journal
  9. 9
  10. 10
  11. 11
    Academic Journal

    Source: Neuromuscular Diseases; № 4 (2014); 12-19 ; Нервно-мышечные болезни; № 4 (2014); 12-19 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2014-0-4

    File Description: application/pdf

    Relation: https://nmb.abvpress.ru/jour/article/view/32/28; Angelucci L., Ramacci M.T. Hypothalamopituitary adrenocortical function in aging: effects of acetyl-L-carnitine. In: Stress, immunity and ageing. A role for acetyl-Lcarnitine, 1989.; Bahring R., Standhardt H., Arrigoni Martelli E., Grantyn R. GABAactivated chloride currents of Postnatal mouse retinal ganglion cells are blocked by Acetylcholine and Acetylcarnitine: how specific are ion channel in immature neurons. Eur J Neurosci 1994;6,1089–9 9.; Bella R., Biondi R., Raffaele R., Pennisi G. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res 1990;10(6):355–60.; Chiechio S., Copani A., DePetris L. et al. Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NFkappa B pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of L-acetylcarnitine. Mol Pain 2006;2:20–8.; Chiechio S., Copani A., Zammataro M. et al. Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. Trends Pharmacol Sci 2010;31(4):153–60.; Fulgente T., Onofrj M., Del Re M.L. et al. L-Acetylcarnitine treatment of senile depression. Clin Trial J 1990;27(3):155–63.; Garzya G., Corallo D., Fiore A. et al. Evaluation of the effects of L-Acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990;16(2):101–6.; Harsing L.G., Sershen H., Toth E. et al. Acetyl-L-carnitine releases dopamine in rat corpus striatum: an in vivo microdialysis study. Eur J Pharmacol. 1992;218(1):117–21.; Hoefer M.E.,Voskanian S.J., Koob G.F., Pulvirenti L. Effects of terguride, ropinirole, and acetyl-L-carnitine on methamphetamine withdrawal in the rat. Pharmacol Biochem Behav 2006;83(3):403–9.; Jones L.L., McDonald D.A., Borum P.R. Acylcarnitines: role in brain. Prog Lipid Res 2010;49(1):61–75.; Madiraju P., Pande S.V., Prentki M., Madiraju S.R. Mitochondrial acetylcarnitine provides acetyl groups for nuclear histone acetylation. Epigenetics 2009;4: 399–403.; Masi F., Leggio B., Nanni G. et al. Effects of long-term acetyl-L-carnitine administration in Rats-II: Protection against the disrupting effect of stress on the acquisition of appetitive behavior. Neuropsychopharmacology 2003;28(4):683–93.; Pettegrew J.W., Levine J., McClure R.J. Acetyl-L-carnitine physical–chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer’s disease and geriatric depression.Mol Psychiatry 2000;5(6):616–32.; Pettegrew J.W., Levine J., Gershon S. et al. 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disord 2002;4(1):61–6.; Pisano C., Pratesi G., Laccabue D. et al. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003;9(15):5756–67.; Pulvirenti G., Valerio C.,Spadaio F. et al. Acetylcarnitine reduces the immobility of rats in a despair test. Behav Neural Biol 1990;54(2):110–4.; Ricciolini R., Scalibastri M., Kelleher J.K. Role of acetyl-L-carnitine in rat brain lipogenesis: implications for polyunsaturated fatty acid biosynthesis. J Neurochem 1998;71(6):2510–17.; Rosca M.G., Lemieux H., Hoppel C.L. Mitochondria in the elderly: is acetylcarnitine a rejuvenator? Adv Drug Deliver Rev 2009;61(14);1332–42.; Taglialatela G., Navarra D., Cruciani R. et al. Acetyl-L-carnitine treatment increase nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats. Exp Gerontol1994;29(1);55–66.; Tempesta E., Janiri L., Pirrongelli C. Stereospec ificeffects of acetylcarnitine on the spontaneous activity of brainstem neurones and their responses to acetylcholine andserotonin. Neuropharmacology 1985;24(1):43–50.; Tempesta E., Casella L., Pirrongelli C. et al. L-acetylcarnitine in depressed elderly subjects. Across-over study vs placebo. Drugs Exp Clin Res 1987;13(7):417–23.; Tolu P., Masi F., Leggio B. et al. Effects of long-term acetyl-L-carnitine administration in rats. Increased dopamine output in mesocorticolimbic areas and protection toward acute stress exposure. Neuropsychopharmacology 2002;27(3):410–20.; Valente M., Koverech A., Canonico P., Grilli M.G. Acetyl-L-carnitine, a new pharmacological modulator of adult hippocampal neurogenesis. Program no. 907.22PosterMM29. 2011 Neuroscience Meeting Planner. Washington, DC, Society for Neuroscience, 2011(online).; Zanardi R., Smeraldi E. A double-blind, randomised, controlled clinical tria lof acetyl- L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharm 2006;16(4):281–7.; https://nmb.abvpress.ru/jour/article/view/32

  12. 12
  13. 13
  14. 14
    Academic Journal

    Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 5, No 3 (2013); 13-17 ; Неврология, нейропсихиатрия, психосоматика; Vol 5, No 3 (2013); 13-17 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2013-3

    File Description: application/pdf

    Relation: https://nnp.ima-press.net/nnp/article/view/247/215; Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27(6):1458–86. DOI:10.2337%2Fdiacare.27.6.1458. Ziegler D, Sohr CG, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care. 2004;27(9):2178–83. DOI:10.2337%2Fdiacare.27.9.2178. Tesfaye S, Chaturvedi N, Eaton SE; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–50. DOI:10.1056%2FNEJMoa032782. Яхно НН. Боль. Москва: МЕДпресс-информ; 2009. 303 с. [Yakhno NN. Bol'. Mosсow: MEDpress-inform; 2009. 303 p.] Кукушкин МЛ., Хитров НК. Общая патология боли. Москва: Медицина; 2004. 144 с. [Kukushkin ML. Obshchaya patologiya boli. Moskva: Meditsina; 2004. 144 р.] Данилов АБ. Нейропатическая боль. Москва: Боргес; 2007. 198 с. [Danilov AB. Neyropaticheskaya bol'. Moskva: Borges; 2007. 198 р.] Каракулова ЮВ, Шутов АА. Изучение гуморального звена серотонинергической системы при хронических болевых синдромах. Росcийский журнал боли. 2011;2:10–1. [Karakulova YuV, Shutov AA. Izuchenie gumoral'nogo zvena serotoninergicheskoy sistemy pri khronicheskikh bolevykh sindromakh. Rosciyskiy zhurnal boli. 2011;2:10–1.] Каракулова ЮВ, Шутов АА. Количественное определение серотонина сыворотки крови в диагностике головных болей напряжения. Клиническая и лабораторная диагностика. 2006;1:9–10. [Karakulova YuV, Shutov AA. Quantitative determination of serum serotonin in the diagnosis of tension headache. Klinicheskaya laboratornaya i diagnostika. 2006;1:9–10.] Kroeze WK. The molecular biology of serotonin receptors therapeutic implication for the interface of mood and psychosis. Biol Psychiatry. 1998;44(11):1128–42. DOI:10.1016%2FS0006-3223%2898%2900132-2. Ткаченко АА. Содержание серотонина в плазме крови и тромбоцитах и показатели захвата серотонина тромбоцитами при нарушении половой идентичности у лиц с аномальным сексуальным поведением. Росcийский психиатрический журнал. 1997;3:37–40. [Tkachenko AA. Soderzhanie serotonina v plazme krovi i trombotsitakh i pokazateli zakhvata serotonina trombotsitami pri narushenii polovoy identichnosti u lits s anomal'nym seksual'nym povedeniem. Rosciyskiy psikhiatricheskiy zhurnal. 1997;3:37–40.] Artigas F. Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium. Psychopharmacology (Berl). 1989;99(3):328–32. DOI:10.1007%2FBF00445552. Отеллин ВА. Формирование патологий головного мозга в эмбриональный период. Природа. 2003;(9):23–8. [Otellin VA. Formirovanie patologiy golovnogo mozga v embrional'nyy period. Priroda. 2003;(9):23–8.] Гомазков ОА. Плейотропные эффекты нейротрофинов. Принципы терапевтического действия церебролизина. Москва: ООО КДМ; 2010. 136 с. [Gomazkov OA. Pleyotropnye effekty neyrotrofinov. Printsipy terapevticheskogo deystviya tserebrolizina. Moscow: OOO KDM; 2010. 136 р.] Fujimura H, Altar C, Chen R et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Tromb Haemost. 2002;87(4):728–34. Pearse AG. The common peptides and the citochemistry of their cells of origin. Basic Appl Histochem. 1980;24(2):63–73. Lesch KP, Bengel D, Heils A et al. Assoсiation of anxiеty-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274(5292):1527–31. Karege F, Perrez G, Bondolfi G et al. Decreased serum brain-derived neurutrophic factor levels in major depressed patients. Psychiatry Res. 2002;109(2):143–8. DOI:10.1016%2FS0165-1781%2802%2900005-7. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150(3):573–81. DOI:10.1016/j.pain.2010.06.019. Строков ИА, Моргоева ФА. Стратегия профилактики и лечения неврологических осложнений сахарного диабета. В сб.: Опыт применения актовегина в эндокринологии. Москва; 2005. C. 47–55. [Strokov IA, Morgoeva FA. Strategiya profilaktiki i lecheniya nevrologicheskikh oslozhneniy sakharnogo diabeta. V sb.: Opyt primeneniya aktovegina v endokrinologii. Moscow; 2005. Р. 47–55.] Dworkin RH, O'Connor AB, Backonja M et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(2):237–51. DPO: 10.1016%2Fj.pain.2007.08.033. Epub 2007 Oct 24. Ziegler D, Movsesyan L, Mankovsky B et al. Treatment symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32(8):1479–84. DOI:10.2337/dc09-0545. Epub 2009 May 26.

  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20